VIDEO: FXR agonists provide multiple hepatic improvements in NASH

BOSTON — In this exclusive video from The Liver Meeting 2019, Arun Sanyal, MD, professor of medicine at Virginia Commonwealth University, highlights new data on emerging therapeutics for nonalcoholic steatohepatitis presented at the meeting.“This year at the meeting, several important studies were presented, which reflect significant advances in the treatment of NASH,” Sanyal told Healio…

FDA warns 15 companies for selling products containing CBD

The FDA recently issued warning letters to 15 companies for illegally selling products containing cannabidiol, or CBD, according to a press release.The warning letters state that the companies use product webpages, online stores and social media to market CBD products in interstate commerce; market CBD products as dietary supplements; and/or add CBD to human and…

Complete endoscopic healing linked with better Crohn’s outcomes

Patients with Crohn’s disease who achieved complete mucosal healing experienced better outcomes than those who just had partial healing, according to study results.Mathurin Fumery, MD, PhD, of Amiens University Hospital in France, and colleagues wrote that mucosal healing is considered a crucial therapeutic target in CD and has been explored in numerous studies.“However, the optimal…

US life expectancy drops after decades of improvement

Life expectancy among adults in the United States increased for nearly 6 decades, reaching 78.9 years in 2016, but it slowed over time and then dropped for 3 straight years after 2014, according to a special communication published in JAMA.“The implications for public health and the economy are substantial, making it vital to understand the…

Low-volume bowel prep still effective, but better tolerated

Low-volume, split-dose bowel preparations were just as effective as high-volume preps with the added benefit of being better tolerated by patients, according to the results of a metanalysis.“Suboptimal patient compliance and acceptability have been attributed to the large volume of bowel preparation to be administered, affecting patient experience and willingness to repeat the procedure,” Marco…

Value-based agreements for acute hepatic porphyria therapy Givlaari launch

Alnylam Pharmaceuticals announced a new and enhanced framework for value-based agreements designed to provide access to the recently FDA-approved Givlaari for patients with acute hepatic porphyria, according to a press release.Alnylam is in active discussions with leading payers about such value-based agreements for Givlaari (givosiran) and Alnylam has reached an agreement in principle with Harvard…

FDA accepts NDA for Ocaliva for the treatment of NASH

The FDA accepted the first new drug application for the treatment of liver fibrosis due to nonalcoholic steatohepatitis; Intercept announced that Ocaliva, already approved for the treatment of primary biliary cholangitis, has a PDUFA date of March 26, 2020.“If approved, OCA would be the first available therapy for patients with fibrosis due to NASH, a…